Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

Summary

The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week

Timeline

Start

2024-01-13

Primary completion

2025-06-11

Completion

2025-12-12

Outcome

Met primary endpoint

release “MG-K10已在成人中重度AD的一项随机、双盲、安慰剂对照III期临床研究取得阳性结果，达到方案设计的临床试验主要研究终点” mabgeek.com ↗

Drugs

Indications